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Background: Several studies have described the use of popliteal-to-distal bypass grafts, mostly in patients with diabetes
mellitus who show tissue loss and represent a high-risk population. The study objective was to conduct meta-analysis to
assess the long-term primary and secondary patency and foot preservation after popliteal-to-distal bypass grafts.
Methods: Data was retrieved from studies published from 1981 through 2004 that were identified from an electronic
database. Thirty-one series that used survival analysis reported a 1-year graft patency rate and included at least 15
bypasses. Data from life tables, survival curves, and texts were used to calculate an interval success rate for each month in
each series of grafts. Monthly success rates were combined across series to obtain a pooled estimate of success for each
month, according to a random-effects protocol for meta-analysis. Pooled survival curves were then constructed for graft
patency and foot preservation.
Results: The 5-year pooled estimate standard error was 63.1% 4.3% for primary patency, 70.7% 4.6% for secondary
patency, and 77.7%  4.3% for foot preservation. There was a superiority trend favoring reversed vein grafts and tibial
bypasses that became more apparent in sensitivity analysis. No publication bias was detected.
Conclusion: The popliteal-to-distal vein bypass is a tool of high efficiency in the treatment of severe, chronic critical
ischemia in the lower extremity. ( J Vasc Surg 2006;43:498-503.)The tradition of placing the proximal anastomosis of
infrainguinal bypasses in the common femoral artery pre-
vailed until 1981, when Veith et al1 proposed the short
bypass principle. This principle involves the use of more
distal sites for the origin of the bypass and combines the
advantages of avoiding groin dissection, requiring less graft
material, using shorter incisions, and reducing operative
time. The popliteal-to-distal (PD) bypass graft often uses
the great saphenous vein (GSV), has evolved as the most
typical short bypass, but is applicable to only a small fraction
of patients who have a nearly normal popliteal pulse and
absent pedal pulses. Despite concern over the progression
of disease in the superficial femoral artery (SFA), the few
reports that have addressed this problem have shown low
rates of progression.2-7
With the use of percutaneous transluminal angioplasty
for short lesions in the SFA, there has been a slight increase
in the applicability of PD bypasses. 4,8 On the other hand,
angioplasty of infrapopliteal arteries has become a viable
alternative to PD bypass.9 Because diabetic patients are
particularly prone to develop tibioperoneal occlusion with
minimal disease in the SFA, these patients represent the
main target for PD bypass grafting when critical ischemia
develops. Furthermore, the ischemic diabetic foot with
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498superimposed infection often creates an urgent need for a
PD bypass to salvage the limb. The increasing prevalence of
diabetes mellitus in the ageing world population and the
competing interests in endovascular procedures justify a
reassessment of all types of bypass grafting. The current
meta-analysis assessed long-term outcomes after PD bypass
grafting.
METHODS
Study identification. The senior author (M. A.) searched
articles published from January 1981 through December
2004 in the databases of MEDLINE, EMBASE, and
LILACS. The descriptors popliteal to distal bypass and pedal
bypass listed 1113 and 637 titles, respectively. Several words
were searched in these titles, including pedal, dorsalis, dor-
sal, plantar, distal, inframalleolar, foot, popliteal, tibial, and
peroneal. After reading the abstracts online, 79 articles were
printed for complete reading. Articles referenced were read
selectively, but the final meta-analysis included 31 arti-
cles,2-32 all of which were identified from the databases
(Appendix A, online only).
Criteria for inclusion. The articles included satisfied
the following criteria: (1) a minimum of 15 PD grafts, (2) a
greater number of PD grafts than femoral-to-distal grafts,
when these procedures had not been described separately,
(3) use of survival analysis to describe outcomes, and (4) a
minimum follow-up of a year, at least for some grafts. If six
articles5,6,21,26,28,31 that contained 112 femoral-to-distal
bypasses were excluded, then 243 PD bypasses would also
be excluded. Although a single center has reported more
than one study on the subject,15,16,31 no bypass was in-
cluded more than once.
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included primary patency (PP), secondary patency (SP),
and foot preservation (FP), which have mostly been re-
ported as recommended.33 Although PP and SP reflect the
fate of arterial reconstructions better, FP describes the fate
of revascularized limbs, which also depends on other factors
such as vascular disease in the foot, diabetic neuropathy,
and ongoing pedal sepsis. The survival data were described
in the original studies by using life tables of different
structures, survival curves, and texts (Appendix B, online
only).
Data extraction. Two authors (M. R. and F. C. B. N.)
retrieved the data from life tables and from survival curves
that showed the number of units (bypasses or limbs) at risk
for all intervals, and the senior author (M. A.) retrieved the
data from less complete survival curves and from texts.
Occasionally, data from a text combined with a life table or
survival curve were used to generate data for a different
outcome.4,9,15,25,26 The data extracted from each study
were confirmed by a second observer. The articles included
usually reported on the sites of proximal and distal anasto-
moses and on the graft materials used but often omitted
the rates of secondary bypasses (Appendix A, online
only). The mean age and the rates of male gender,
hypertension, diabetes, and smokers were also occasion-
ally omitted (Table I).
Meta-analysis of subgroups. Despite the missing
data in some articles, the PD graft series were classified
according to the predominant outflow artery, whether a
tibial bypass (n 17) or a pedal bypass (n 15). The tibial
bypass series contained 637 tibial or peroneal bypasses, 314
pedal bypasses, and 11 other procedures. The pedal bypass
series contained 227 tibial or peroneal bypasses, 1147 pedal
bypasses, and 1 femoropopliteal bypass. The PD graft series
was also classified according to the predominant graft con-
figuration, whether reversed GSV (n 14) or nonreversed
GSV (n  13). In situ GSV series and translocated GSV
Table I. Demographic and surgical variables for 29
popliteal-to-distal vein bypass graft series
Original
series
Studies with
no data
Grafts 1 2320 0
Mean age 66.0 (60.0, 72.0) 6
Male sex 72.4 (50.0, 92.3) 8
Hypertension 55.2 (16.2, 82.4) 14
Diabetes mellitus 86.3 (40, 100) 5
Smoking 40.7 (11.0, 90.2) 11
Heart disease 51.3 (21.9, 70.0) 12
Second bypass 10.0 (0.0, 28.6) 21
Tissue loss 87.9 (53.8, 100) 7
Renal failure 19.3 (2.4, 65.3) 15
GSV 87.5 (0.00, 100) 6
Proximal anastomosis AK 28.1 (0.00, 70.6) 6
Pedal bypass 62.0 (0.00, 100) 1
Censored within one year 37.0 (6.7, 52.4) 0
GSV, Great saphenous vein; AK, above-knee.
Values are weighted means (range).series were studied together.Study quality. An ideal study should contain the rate
of patients requiring PD grafts, life tables rather than
graphs, the 1-month follow-up interval, an account for loss
to follow-up, and the use of PP, SP, and FP. Of particular
relevance is a link between predictive variables and each life
table. Other relevant items are the rates of primary bypasses
and tissue loss, regimens of postoperative antithrombotic
therapy, the number of patent grafts that did not avoid a
major amputation, the number of limbs with disease pro-
gression in the SFA, data on further bypasses, and the
absence of a flat tail in the survival curve. Hence, a perfect
study would score 15, with a decrease of one point for each
unmet requirement. No blinding process was used.
Statistical methods. Random-effects meta-analysis
implies that the studies combined are a random sample of a
universe of studies. On the other hand, fixed-effects meta-
analysis estimates a single common effect for all studies.
The former was preferred because patients, surgeons, and
quality of care differ worldwide. Random-effects meta-
analysis combined monthly hazard rates from single series
to yield a pooled estimate of success for each month of
follow-up (Fig 1). The product of successive, monthly
pooled estimates of success then yielded a pooled measure
of success for each group or subgroup. Between-study and
between-interval variances were calculated as previously
reported to reduce the influence of study size on the pooled
estimates.34 This was done separately for PP, SP, and FP,
and a standard error was calculated for each pooled estimate
at each yearly interval.34 The differences between sub-
groups were measured at yearly intervals and assessed sta-
tistically according to Schenker and Gentleman.35 This
method judges the significance of differences by examining
the overlap between confidence intervals and does not
calculate P values.
Sensitivity analysis. First, fixed-effectsmodelling,which
differs from random effects by assuming null between-study
variances, was used to obtain decreased standard errors and
be less conservative in the comparison of subgroup meta-
analyses.
Second, bias was present in the original studies, which
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Fig 1. Random-effects meta-analysis of popliteal-to-distal bypass
grafts for primary patency (gray line), secondary patency (black
line), and foot preservation (red line).assumed independence between events and losses to
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ments were done in the original data: (1) a percentage of
censored units representing losses to follow-up of 10% in
each month within the first year of follow-up, and (2) 60%
of units considered as lost represented additional failures.
The rate of 10% was obtained from articles that described
withdrawals in detail,3,11,24,26 and the rate of 60% was an
extreme assumption used in a similar meta-analysis.34
Third, selective exclusion was applied to the largest
study,16 which contained only bypasses to the dorsal pedis
artery; five studies4,17,26,28,30 that used plain curves or texts
to describe graft survival, five studies5,6,21,26,28 that con-
tained femoral-to-distal bypasses, five studies12,14,25,27,30
that scored 8 for quality, and the flat tails of 20 stud-
ies.2,4,6-15,18,21,22,24,26,29,30,32
Finally, publication bias was investigated by using fun-
nel plots (Fig 2).
RESULTS
Characteristics of the original studies. The country
of origin was the United States for 21 studies, Germany for
three studies, Italy for two studies, Brazil for two studies,
and Spain, Belgium, and Finland for one study each. The
31 studies were scored for quality from 3 to 12 (median, 9)
(Appendix A, online only). The median was 1995 for the
year of publication and 48 subjects for study size. There was
a wide predominance of diabetes mellitus, tissue loss, and
use of GSV grafts (Table I). Eight prosthetic grafts were
used, but excluding the corresponding studies would also
0
50
100
150
200
250
300
350
400
450
500
550
600
40% 50% 60% 70% 80% 90% 100%
2-year PP in the original studies
S
tu
d
y
 s
iz
e
Fig 2. Funnel plots of study size vs 2-year primary patency (PP)
in the original studies. Symmetry around the 2-year pooled PP
(vertical bar) does not indicate publication bias.exclude 836 PD vein grafts. Only two bypasses were donein patients with claudication. Survival analysis used mainly
life tables (PP, n  10; SP, n  9; FP, n  8) and survival
curves that showed the number at risk for all intervals (PP,
n  10; SP, n  11; FP, n  9) or for some intervals (PP,
n 5; SP, n 6; FP, n 3). A few articles showed survival
curves that omitted the number at risk (PP, n  1; SP,
n  2; FP, n  2) or used texts alone or combined with
another tool (PP, n 2; SP, n 4; FP, n 6). All articles
showed a life table or a survival curve for at least one main
outcome.
The early mortality rate described in 30 articles was 0%
to 11.5% (weighted average, 2.3%) and was slightly smaller
for tibial graft series (2.0%) than for pedal graft series (2.6%)
(2 test  0.136; degrees of freedom  1; P  0.71). The
1-year cumulative death rate calculated for 22 articles was
5.6% to 27.0% (weighted average, 13.1%). Twenty-one
articles described the percentage of patent grafts that did
not avoid a major amputation, which was 0% to 11.6%
(weighted average, 4.3%). Seven articles described disease
progression in the SFA or proximal to this artery that was
1.8% to 5.9% (weighted average, 4.3%).
Graft patency and limb salvage. The pooled estimate
of success was 93.3%  1.1% for PP, 94.9%  1.0% for SP,
and 95.1% 1.2% for FP at 1 month, and 63.1%  4.3%,
70.7%  4.6%, and 77.7%  4.3%, respectively, at 5 years
(Table II). The monthly pooled failure rate decreased
progressively for all three outcomes to 1% at 8 months
and remained below this level thereafter. The differences in
the subgroup meta-analysis were not significant at yearly
intervals (Table III).
A complete transmetatarsal amputation was required
for nearly 15% of the patients in some original PD graft
studies,2,15,19,22,26 but in one study,17 this procedure was
done in 31%. Toe and ray amputation were done evenmore
frequently.
Sensitivity analysis. The fixed-effects model produced
small increases in the 5-year pooled estimates (Table IV)
but revealed a significant difference at 1 and 2 years in the
comparison of nonreversed vs reversed GSV grafts for both
PP and SP, as well as in the comparison of tibial graft
series with pedal graft series for SP. Adjustments for lost
follow-up and the selective exclusion of studies changed the
5-year pooled estimates by 4% (Table IV), with no alter-
Table II. Meta-analysis estimates for the main outcomes
Month PP(%) SP(%) FP(%)
93.3 (1.1) 94.9 (1.0) 95.1 (1.2)
3 89.7 (1.5) 92.2 (1.4) 93.0 (1.6)
6 85.8 (2.1) 89.3 (1.6) 90.9 (1.9)
12 81.5 (2.0) 85.9 (1.9) 88.5 (2.2)
24 76.8 (2.3) 81.6 (2.3) 85.2 (2.5)
36 72.3 (2.7) 76.7 (2.9) 82.3 (3.0)
48 68.6 (3.3) 73.6 (3.5) 80.7 (3.6)
60 63.1 (4.3) 70.7 (4.6) 77.7 (4.3)
PP, Primary patency; SP, secondary patency; FP, foot preservation.
Values are pooled estimates (standard-errors).ation in the statistical significance. When the flat tails from
ondary
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and 4.4% for PP, 1.6% and 4.1% for SP, and 1.1% and 2.2%
for FP at 4 and 5 years, respectively.
For a study size of 50 grafts, the 2-year estimate was
higher than the 2-year pooled estimate in five of 14 series
for PP and in six of 16 series for SP. Consequently, small
series that showed better results were not published selec-
tively.
DISCUSSION
Meta-analysis of uncontrolled surgical series represents
the best source of evidence when randomized trials do not
exist and when the available studies are reasonably homog-
enous, as is the case for PD bypass grafts. Clearly, the
current meta-analysis included studies that described com-
parable patients and used similar methods of analysis. All
but two patients had critical ischemia, most patients had
diabetes, and vein grafts were used wherever possible. Only
five studies failed to describe all three main outcomes, and
only two studies did not present a survival curve of good
Table III. Meta-analysis of graft patency and foot salvage
Studies/grafts 1 yr (%)
PP
Reversed GSV 13/90 83.1 (2.7)
NR GSV 10/1024 77.7 (3.8)
PP
Pedal bypass 11/1266 77.4 (3.5)
Tibial bypass 16/871 84.7 (2.5)
SP
Reversed GSV 14/911 87.5 (2.7)
NR GSV 13/1186 84.1 (3.3)
SP
Pedal bypass 14/1361 81.1 (3.1)
Tibial bypass 16/918 89.8 (2.3)
FP
Reversed GSV 13/889 87.7 (2.7)
NR GSV 10/1019 87.5 (4.3)
FP
Pedal bypass 11/1261 88.4 (4.2)
Tibial bypass 16/900 87.5 (2.4)
PP, Primary patency; GSV, great saphenous vein; NR, nonreversed; SP, sec
Table IV. Sensitivity analysis of graft patency and foot
salvage
Procedure PP (%) SP (%) FP (%)
Fixed-effects modelling 2.0 1.4 3.2
Adjustments for loss to follow-up 1.4 2.3 3.7
Exclusions
Largest study 2.6 2.0 1.3
Plain curves and texts 0.8 1.2 0.6
Femoral-to-distal bypasses 1.4 2.7 2.3
Quality score 8 3.4 1.0 0.8
Flat tails 4.4 4.0 2.3
PP, Primary patency; SP, secondary patency; FP, foot preservation.
Values are changes in the 5-year pooled estimates.quality or a life table. Not surprisingly, 21 studies cited therecommendations of Rutherford et al33 or a previous ver-
sion.
A flat segment in a survival curve conveyed biased
information on the risk of failure within the corresponding
interval. Meta-analysis of PD grafts eliminated the problem
of long flat tails seen in most original studies, thereby
avoiding the overestimation of graft patency and limb
salvage2 years. The current study also showed that PD
grafts were technically highly successful and remarkably
stable 8 months, even when the flat tails were elimi-
nated.
A major advantage of PD bypass grafts is the possibility
of frequently using the GSV, although the choice of graft
configuration remains a matter of preference. In situ vein
grafting may not allow use of the best portion of available
vein and often implies using parallel incisions at the ankle,
whereas excised veins obviate these problems and allow the
use of a tapered conduit. The nonreversed translocated
GSV is therefore particularly suitable for infrapopliteal re-
vascularization.12,16,18
In a flexible approach to pedal revascularization, sur-
geons from a prestigious center used this configuration in
15% of the cases until 1989 and in 31% thereafter.15,16 In
contrast, most studies on PD grafts have shown a prefer-
ence for the reversed configuration, perhaps because PD
grafts are essentially short grafts and because reversed GSVs
may also have a natural tapering.16 Such a preference seems
justified because the differences in pooled patencies favored
the reversed GSV, although not significantly. The alterna-
tive use of fixed-effects modelling yielded significant differ-
ences in the pooled patencies at 1 and 2 years, however.
This statistical procedure was easily justifiable because the
patients sampled were homogenous and the corresponding
changes in the pooled estimates were small. Other proce-
dures in the sensitivity analysis had little impact on the
ubgroups
yr (%) 3 yr (%) 4 yr (%) 5 yr (%)
1 (3.1) 74.4 (3.9) 68.9 (5.2) 65.9 (6.6)
2 (4.3) 69.0 (5.1) 66.7 (6.8) 58.5 (7.8)
4 (3.7) 68.3 (4.4) 65.6 (4.9) 56.6 (5.6)
3 (2.9) 75.4 (3.5) 70.0 (4.8) 68.6 (5.6)
5 (3.1) 78.9 (4.0) 74.0 (4.8) 73.2 (6.3)
9 (3.9) 74.0 (4.8) 71.9 (6.0) 66.5 (7.7)
8 (3.6) 72.1 (4.6) 69.8 (5.2) 65.4 (6.3)
6 (2.8) 80.4 (3.4) 75.9 (4.7) 75.5 (6.1)
6 (3.2) 82.9 (3.5) 81.1 (4.3) 79.7 (5.4)
4 (4.6) 81.2 (6.1) 79.8 (7.3) 75.3 (8.4)
5 (4.4) 81.4 (5.3) 79.6 (6.8) 75.7 (7.3)
5 (2.9) 82.9 (3.4) 81.2 (4.0) 79.8 (5.0)
patency; FP, foot preservation.for s
2
79.
73.
72.
80.
84.
78.
76.
85.
85.
84.
84.
85.outcomes and did not reveal any statistical significance.
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both applicable, some surgeons prefer the dorsal pedal
bypass to obtain more complete foot revascularization and
avoid major amputation in the presence of a patent graft.16
Obviously, this choice negates the short-graft principle.
The comparison of tibial graft series and pedal graft series
was thus of some practical importance. Random-effects
modelling revealed no significant difference favoring the
former series, but fixed-effects modelling yielded a signifi-
cant difference at 1 and 2 years. Despite the superiority
trend of tibial graft series, the pooled FP differed by1% at
these two times. A properly indicated tibial or peroneal
bypass is possibly as effective as a longer pedal bypass for
limb salvage.36
Because patients undergoing PD bypass grafting gen-
erally have chronic critical limb ischemia, FP becomes an
outcome of particular interest. Unfortunately, FP does not
provide information of the effects on rest pain nor does it
measure the incidence of complete ulcer healing and minor
amputation, all of which limit walking ability and quality of
life. Walking ability and quality of life are better after
revascularization, even with a moderate foot salvage rate,
than after primary below-knee amputation.37 In diabetic
patients, however, the well-known complications in target
organs may further reduce the quality of life.38
The present meta-analysis provided a basis against
which infrapopliteal angioplasty should be compared. An
early mortality rate averaging 2.3% in PD graft series may
compare unfavorably with angioplasty, whereas a pooled
FP of 88.5% at 1 year and the remarkable stability of PD
grafts 7 months represent a major challenge to interven-
tionalists.
Bias was small in this meta-analysis. The adjustments
for incomplete follow-up showed only small decreases in
the pooled patencies, and the inflating effect of flat tails
from the original studies was corrected. Clinical symp-
toms, graft material, and level of proximal anastomosis
were mostly restricted by design, whereas subgroup meta-
analysis partly assessed the influence of graft configuration
and outflow artery. Except for runoff, no other predictor of
graft patency is well recognized.
CONCLUSION
The internal and external validity of inferences from
this meta-analysis were strongly supported. The studies
reviewed adopted similar outcomes, provided data of high
quality, and described high response rates. In addition, the
study design, particularly the criteria for inclusion, was
compatible with real life and allowed an adequate sampling
of a hypothetic population of studies. Finally, random-
effects modelling avoided undue precision, and sensitivity
analysis clarified several points. In the absence of bias and
study invalidity, we conclude that PD vein grafts for critical
ischemia provide excellent outcomes and should be used
confidently in suitable patients.AUTHOR CONTRIBUTIONS
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First author Size DM (%) Tissue loss (%) Pedal bypass (%) GSV (%) Flat tail Early deaths (%)
Andros 88 76.1 85.2 38.6 85.2 2.3
Ballard 43 87.5 67.4 16.3 100  2.3
Biancari 66 78.8 100 72.7 93.9  6.1
Brothers 62 40 71 61.3 Unk  1
Brown 52 88.2 69.2 21.2 94.2 1.9
Cantelmo 32 71.9 Unk 25 93.8  0
Cavallini 15 100 100 86.7 86.7 0
Davidson 31 Unk 100 Unk Unk  0
Eckstein 21 Unk Unk 61.9 Unk  4.8
Frankini 43 78 93 62.8 95.3 4.7
Gloviczki 48 Unk Unk 100 Unk  0
Goyal 21 81 76.2 0 0  4.8
Grego 71 77.5 69 9.9 57.7 2.8
Harrington 73 78 79 100 97.3  1.4
Hughes 98 83.7 94.9 100 68.4 1
Marks 32 65.5 Unk 34.4 100 6.3
Mills 56 86.8 98.1 39.3 96.4  5.4
Mohan 35 100 94.3 28.6 85.7  0
Monux Ducaju 30 70 70 46.7 93.3  3.3
Ouriel 21 81 66.7 0 0 4.8
Pereira 20 65 100 65 85  5
Pomposelli 556 91.9 74.8 100 80 1
Rhodes 26 96.2 53.8 15.4 100  11.5
Rosenbloom 49 76 85.7 36.7 93.9 0
Schmiedt 140 100 96 50 Unk  1.4
Schneider 64 100 100 66.9 100  1.6
Shah 106 78.3 Unk 38.7 63.2  2.8
Stonebridge 124 100 83.9 61.3 89.5  0.8
Verhelst 44 91.7 88.6 44.2 95.5  0
Wengerter 153 87 92.2 24.2 94.1  3.9
Wölfle 130 100 97.7 48.5 96.9  2.3
DM, Diabates mellitus; GSV, great saphenous vein; Unk, unknown.
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First
author
Life
table
1-month
interval
Description
of losses
Censored
1-yr (%)
Outcome
measures Risk-set
Quality
score
Andros  43.2 SP 5
Ballard   44.2 All 3  11
Biancari   21.2 All 3  8
Brothers  41.9 All 3  9
Brown   17.3 All 3  12
Cantelmo  28.1 All 3  9
Cavallini  6.7 All 3  8
Davidson    35.5 SP 8
Eckstein  42.9 SP 3
Frankini   16.3 SP FP  9
Gloviczki  25 PP SP 5
Goyal  42.9 All 3  9
Grego  14.1 All 3  10
Harrington    23.3 All 3 9
Hughes   27.6 All 3  11
Marks   46.9 All 3  10
Mills   50 All 3  11
Mohan  22.9 All 3  9
Monux Ducaju   33.3 All 3  11
Ouriel  42.9 All 3  10
Pereira   10 All 3  11
Pomposelli  50.4 All 3  8
Rhodes  23.1 All 3  6
Rosenbloom   44.9 All 3  10
Schmiedt  18.6 All 3  6
Schneider  32.8 All 3  9
Shah   49.1 All 3  11
Stonebridge  52.4 All 3  8
Verhelst  22.7 All 3  9
Wengerter  31.4 All 3  9
Wölfle    30 All 3  11SP, Secondary patency; FP, foot preservation; PP, primary patency.
